Food and Drug Administration

Oncologic Drugs Advisory Committee

December 14, 1999

Slides

Disclaimer

The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

Therapeutic Equivalence & Active control Clinical Trials, Dr. Richard Simon, DSc, FDA  htm  ppt

Celebrex Capsules (Celecoxib) Familial Adenomatous Polyposis (FAP), Dr. Richard Spivey, PharmD, PhD, Worldwide Regulatory Affairs Searle  pdf

Indication, Reduction and Regression of Adenomatous Colorectal Polyps in Familial Adenomatous Polyposis Patients, Dr. Judy Chiao, MD, FDA  htm  ppt